DTB No 4. Lixisenatide, Lyxumia® in type 2 Diabetes Mellitus

Content tools

Share it

One more, but not getting ahead

There are no clinical trials on the impact on mortality and the micro and macrovascular complications of diabetes.
It has only shown greater efficacy in the reduction of HbA1C (difference vs placebo between -0.32% and -0.74%).
Long-term safety remains unknown (thyroid gland related, cardiovascular adverse effects and pancreatitis)
There are no advantages in efficacy, safety, posology or cost vs either the antidiabetic agents currently available or other GLP-1 agonists.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *